These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33140575)

  • 1. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
    Boye K; Ross M; Mody R; Konig M; Gelhorn H
    Diabetes Obes Metab; 2021 Feb; 23(2):508-519. PubMed ID: 33140575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
    Matza LS; Cutts KN; Stewart KD; Norrbacka K; García-Pérez LE; Boye KS
    Qual Life Res; 2021 Jul; 30(7):2033-2043. PubMed ID: 33886044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.
    McEwan P; Baker-Knight J; Ásbjörnsdóttir B; Yi Y; Fox A; Wyn R
    Eur J Health Econ; 2023 Mar; 24(2):187-196. PubMed ID: 35526173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
    Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
    Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
    Shubrook JH; Radin M; Ali SN; Chubb B; DiPietrantonio K; Collings H; Wyn R; Smith M
    Adv Ther; 2022 Sep; 39(9):4114-4130. PubMed ID: 35797004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.
    Takahara M; Shiraiwa T; Katakami N; Maeno Y; Yamamoto K; Shiraiwa Y; Yoshida Y; Kozawa J; Shimomura I
    Intern Med; 2024 Jan; 63(1):43-50. PubMed ID: 37225492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan.
    Sen R; Shields AL; Atsuda K
    J Health Econ Outcomes Res; 2016; 4(1):55-66. PubMed ID: 37663012
    [No Abstract]   [Full Text] [Related]  

  • 16. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
    Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
    Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.
    Hauber AB; Tunceli K; Yang JC; Gantz I; Brodovicz KG; Alexander CM; Davies MJ; Radican L
    Diabetes Ther; 2015 Mar; 6(1):75-84. PubMed ID: 25586555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.